Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.81 - $8.13 $53,576 - $240,648
-29,600 Reduced 80.87%
7,000 $12,000
Q2 2024

Aug 14, 2024

BUY
$5.84 - $17.56 $164,688 - $495,191
28,200 Added 335.71%
36,600 $220,000
Q1 2024

May 15, 2024

SELL
$10.95 - $16.79 $20,805 - $31,901
-1,900 Reduced 18.45%
8,400 $93,000
Q4 2023

Feb 14, 2024

BUY
$4.81 - $15.38 $47,137 - $150,724
9,800 Added 1960.0%
10,300 $153,000
Q3 2023

Nov 14, 2023

SELL
$4.19 - $7.35 $3,352 - $5,880
-800 Reduced 61.54%
500 $2,000
Q2 2023

Aug 14, 2023

BUY
$4.37 - $9.56 $4,807 - $10,516
1,100 Added 550.0%
1,300 $9,000
Q1 2023

May 15, 2023

SELL
$4.52 - $11.71 $5,423 - $14,052
-1,200 Reduced 85.71%
200 $0
Q4 2022

Feb 14, 2023

BUY
$9.51 - $12.95 $13,314 - $18,130
1,400 New
1,400 $15,000

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $68.9M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.